Novartis’ experimental cancer treatment wins endorsement of FDA advisers
The U.S. Food & Drug Administration (FDA) on Wednesday endorsed a first-of-its-kind cancer treatment that makes use of patients’ revved-up immune cells to fight back the deadly disease.
Advisers to the FDA recommended approval of a new experimental cancer treatment called CAR-T therapy for kids with leukemia. The new treatment retrains the patient’s immune system to kill tumor cells.
Oncologic Drugs Advisory Committee member Timothy Cripe, an oncologist with Nationwide Children’s Hospital in Ohio, said the recommendation for the treatment was the most exciting thing she had seen in her lifetime.
However, Dr. Wilson Bryan, who directs the agency’s office that oversees these kinds of treatments, said it would be difficult to standardize.
Commenting on the treatment, Dr. Bryan said, “Particularly, we are concerned that the same safety and benefit seen in clinical trials may not translate into routine use. This is a complex product.”
The recommendation from the federal agency’s Oncologic Drugs Advisory Committee indicates that Novartis’ experimental treatment can be approved by the agency by the end of September this year.
A Translational Pharmaceutics stage, Quotient Clinical connoting its new personality to Quotient Sciences resulting acquirements of SeaView Research, QS Pharma, and Co-Formulate.
Intelligent and connected vehicles are turning into the Chinese business' specialty in the new automotive era. TuSimple Inc. reveals demonstrates minds-off automated driving using two modified trucks in Shanghai.
Well-known for its technology innovation, China region unveiled the first picture of the hypersonic strike airplane that is being created to convey atomic warheads through U.S. rocket protections. The pictures of four distinct rockets that U.S.
New York-based broad communications partnership, Time Inc. uncovered another advanced stage called Time Inc. Latino. Through its new computerized stage Time conveys exceptional access to the U.S. Hispanic group of viewers.
Chinese Multinational Telecommunication Equipment company, ZTE corporation officially released TECS 6.0. The company released the new generation cloud platform at the OpenStack Summit Sydney.
German-based, multinational open-source software company SUSE combines Cloud Foundry and Kubernetes to accelerate application delivery, which also helps to increase business agility.